NMDA agonists and as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

Harvard Review of Psychiatry

Volumn 7, Issue 3, 1999, Pages 125-143

  Krystal, John H ^a,b,c   D'Souza, D Cyril ^a,b   Petrakis, Ismene L ^a,b   Belger, Aysenil ^a,b   Berman, Robert M ^a,c   Charney, Dennis S ^a,b,c   Abi Saab, Walid ^a,c   Madonick, Steven ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CYCLOSERINE; DEXTROMETHORPHAN; DIZOCILPINE; FELBAMATE; GLUTAMATE RECEPTOR; GLYCINE RECEPTOR; KETAMINE; KYNURENIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; REMACEMIDE;

ALZHEIMER DISEASE; ANXIETY NEUROSIS; CHRONIC PAIN; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPILEPSY; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; BRAIN DISEASE; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN EXPERIMENT; MEDICAL ETHICS; METABOLISM; PAIN; SYNDROME; UNITED STATES;

BRAIN DISEASES; CHRONIC DISEASE; ETHICS, MEDICAL; HUMAN EXPERIMENTATION; HUMANS; MENTAL DISORDERS; PAIN; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SYNDROME; UNITED STATES;

EID: 0033190699     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/hrp.7.3.125     Document Type: Review

References (214)

1. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiatry 1959;81:363-9.
2. 3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979; 76:5372-6.
3. Cotman CW, Kahle JS, Miller SE, Ulas J, Bridges RJ. Excitatory amino acid neurotransmission. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven, 1995:75-86.
4. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA. NMDA receptors: from genes to channels. Trends Pharmacol Sci 1996; 17:348-55.
5. 3H]MK-801 binding sites in the human brain. Brain Res 1989;489:397-9.
6. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl- aspartate. Br J Pharmacol 1983;79:565-75.
7. Bear MF, Malenka RC. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol 1994;4:389-99.
8. Yakel JL. Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. Trends Pharmacol Sci 1997;18:124-34.
9. Wheal HV, Chen Y, Mitchell J, Schachner M, Maerz W, Wieland H, et al. Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity. Prog Neurobiol 1998;55:611-40.
10. 2-domain proteins that regulate membrane traffic. Neuron 1996;17:379-88.
11. Snyder SH, Dawson TH. Nitric oxide and related substances as neural messengers. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven, 1995:609-18.
12. Ciabarra AM, Sullivan JM, Gahn LG, Pecht G, Heinemann S, Sevarino KA. Cloning and characterization of χ-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J Neurosci 1995;15: 6498-508.
13. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325: 529-31.
14. D'Souza DC, Charney DS, Krystal JH. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev 1995;1: 227-60.
15. Honer M, Benke D, Laube B, Kuhse J, Heckendorn R, Allgeier H, et al. Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes: preferential interaction of CGP 61594 with NR1/2B receptors. J Biol Chem 1998;273:11158-63.
16. Sucher NJ, Akbarian S, Chi CL, Leclerc CL, Awobuluyi M, Deitcher DL, et al. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci 1995;15:6509-20.
17. Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M. Differential sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport 1993;4:687-90.
18. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990;13:272-6.
19. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
20. Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia: experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm Gen Sect 1993;92:57-65.
21. Krystal JH, Belger A, Abi-Saab W, Moghaddam B, Charney DS, Anand A, et al. Glutamatergic contributions to cognitive dysfunction in schizophrenia. In: Harvey PD, Sharma T, eds. Cognitive functioning in schizophrenia. London: Oxford University Press [In press].
22. Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 1998;155: 726-32.
23. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 1996;3:241-53.
24. Heresco-Levy U, Javitt DC. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 1998;8:141-52.
25. Rison RA, Stanton PK. Long-term potentiation and N- methyl-D-aspartate receptors: foundations of memory and neurologic disease? Neurosci Biobehav Rev 1995;19:533-52.
26. Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology 1998;51(2, suppl 2):S30-5.
27. Soderling TR. Calcium-dependent protein kinases in learning and memory. Adv Second Messenger Phosphoprotein Res 1995;30:175-89.
28. 2+/calmodulin- dependent protein kinase II in the induction of long-term potentiation in hippocampal CA1 area. Neurosci Res 1996;24: 117-22.
29. Lisman J, Malenka RC, Nicoll RA, Malinow R. Learning mechanisms: the case for CaM-KII. Science 1997;276:2001-2.
30. Morris RG, Frey U. Hippocampal synaptic plasticity: role in spatial learning or the automatic recording of attended experience? Philos Trans R Soc Lond B Biol Sci 1997;352: 1489-503.
31. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996;16:2034-43.
32. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC. Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol 1985;5:70-7.
33. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
34. Malhotra AK, Finals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-7.
35. LaPorte DJ, Lahti AC, Koffel B, Tamminga CA. Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients. J Psychiatr Res 1996;30:321-30.
36. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992;260:1209-13.
37. Palmer AM, Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J 1990;4: 2745-52.
38. Schuster GM, Schmidt WJ. D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. Eur J Pharmacol 1992;224:97-8.
39. Fishkin RJ, Ince ES, Carlezon WA Jr, Dunn RW. D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats. Behav Neural Biol 1993;59:150-7.
40. Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 1995;8:226-30.
41. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 1996;46:420-4.
42. Tsai GE, Falk WE, Gunther J. A preliminary study of D- cycloserine treatment in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1998;10:224-6.
43. Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN. D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 1994;8:198-205.
44. Krystal JH, D'Souza DC. D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia. Biol Psychiatry 1998;44:1075-6.
45. Procter AW, Stratmann GC, Francis PT, Lowe SL, Bertolucci PH, Bowen DM. Characterisation of the glycine modulatory site of the N-methyl-D-aspartate receptor-ionophore complex in human brain. J Neurochem 1991;56:299-310.
46. Del Bel EA, Slater P. Binding to the glycine site of the NMDA receptor complex in brains of patients with Alzheimer's disease. Neurosci Lett 1991;131:75-8.
47. Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facultative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 1998;18:2748-63.
48. Lynch G, Kessler M, Rogers G, Ambros-Ingerson J, Granger R, Schehr RS. Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol 1996;11: 13-9.
49. Foster NL, Giordani B, Mellow A, Aronson S, Berent S. Memory effects of low-dose ketamine in Alzheimer's disease. Presented at the 43rd annual meeting of the American Academy of Neurology, Boston, April 1991.
50. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-7.
51. Blanchard BJ, Konopka G, Russell M, Ingram VM. Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer's disease. Brain Res 1997; 776:40-50.
52. Carlson MD, Penney JB Jr, Young AB. NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex. Neurobiol Aging 1993;14:343-52.
53. Ulas J, Brunner LC, Geddes JW, Choe W, Cotman CW. N- methyl-D-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease. Neuroscience 1992;49:45-61.
54. Jansen KL, Faull RL, Dragunow M, Synek BL. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors - an autoradiographic study. Neuroscience 1990;39:613-27.
55. Scheuer K, Maras A, Gattaz WF, Cairns N, Forstl H, Muller WE. Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease. Dementia 1996;7: 210-4.
56. Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease: new hypothesis and new therapeutic strategies. Arch Neurol 1997;54:1234-40.
57. Wu J, Anwyl R, Rowan MJ. β-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 1995;6:2409-13.
58. Koh JY, Yang LL, Cotman CW. β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 1990;533:315-20.
59. Willoughby DA, Rozovsky I, Lo AC, Finch CE. β-Amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. J Mol Neurosci 1995;6:257-76.
60. Millan MJ, Seguin L. Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice. Neurosci Lett 1994;178:139-43.
61. Mercadante S. Ketamine in cancer pain: an update. Palliat Med 1996;10:225-30.
62. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies: what advantages do they offer for the control of pain syndromes? Drugs 1998;55:1-4.
63. Sethna NF, Liu M, Gracely R, Bennett GJ, Max MB. Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. Anesth Analg 1998;86:1250-6.
64. Trujillo KA. Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 1995;13:301-7.
65. Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand 1997;41:1124-32.
66. Warncke T, Stubhaug A, Jørum E. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo. Pain 1997;72:99-106.
67. Rice AC, DeLorenzo RJ. NMDA receptor activation during status epilepticus is required for the development of epilepsy. Brain Res 1998;782:240-7.
68. Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44(11, suppl 8):S14-23.
69. Feinberg I, Campbell IG, Marrs JC. Intraperitoneal dizocilpine induces cortical spike-wave seizure discharges in rats. Neurosci Lett 1995;196:157-60.
70. Dingledine R, Hynes MA, King GL. Involvement of N- methyl-D-aspartate receptors in epileptiform bursting in the rat hippocampal slice. J Physiol 1986;380:175-89.
71. Apland JP, Cann FJ. Anticonvulsant effects of memantine and MK-801 in guinea pig hippocampal slices. Brain Res Bull 1995;37:311-6.
72. Applegate CD, Samoriski GM, Ozduman K. Effects of valproate, phenytoin, and MK-801 in a novel model of epileptogenesis. Epilepsia 1997;38:631-6.
73. Fountain NB, Bear J, Bertram EH III, Lothman EW. Responses of deep entorhinal cortex are epileptiform in an electrogenic rat model of chronic temporal lobe epilepsy. J Neurophysiol 1998;80:230-40.
74. Kubova H, Mares P. Suppression of cortical epileptic afterdischarges by ketamine is not stable during ontogenesis in rats. Pharmacol Biochem Behav 1995;52:489-92.
75. Sagratella S. NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Pharmacol Res 1995;32:1-13.
76. Davies JA. Remacemide hydrochloride: a novel antiepileptic agent. Gen Pharmacol 1997;28:499-502.
77. Subramaniam S, Donevan SD, Rogawski MA. Block of the N-methyl-D-aspartate receptor by remacemide and its desglycine metabolite. J Pharmacol Exp Ther 1996;276:161-8.
78. White HS, Harmsworth WL, Sofia RD, WoIfHH. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 1995;20:41-8.
79. Theodore WH, Albert P, Stertz B, Malow B, Ko D, White S, et al. Felbamate monotherapy: implications for antiepileptic drug development. Epilepsia 1995;36:1105-10.
80. Liddle PF, Fristen KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992;160:179-86.
81. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1995;52:341-51.
82. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi- Dargham A, Abi-Saab D, et al. Interactive effects of subanesthetic ketamine and haloperidol. Psychopharmacology [In press].
83. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi- Dargham A, Morrissey K, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998;135:213-29.
84. Adler CM, Malhotra AK, Goldberg T, Elman I, Pickar D, Breier A. A comparison of ketamine-induced and schizophrenic thought disorder. Presented at the 53rd annual meeting of the Society of Biological Psychiatry, Toronto, May 1998.
85. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998;31(suppl 2):104-9.
86. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 1998;55:354-60.
87. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry [In press].
88. Krystal JH, Belger A, Kirino E, Madonick S, Gatenby CJ, Gore JC, et al. Modulation of cingulate activation to infrequent visual targets by ketamine: a functional MRI study. Presented at the 28th annual meeting of the Society for Neuroscience, Los Angeles, November 1998.
89. Belger A, Kirino E, McCarthy G, Gore JC, Krystal JH. Assessment of prefrontal activation by infrequent visual targets and non-target novel stimuli in schizophrenia: a functional MRI study. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Kona, Hawaii, December 1997.
90. Gruzelier J, Seymour K, Wilson L, Jolley A, Hirsch S. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry 1988;45:623-9.
91. Kolb B, Whishaw IQ. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. J Nerv Ment Dis 1983; 171:435-43.
92. Brebion G, Amador X, Smith MJ, Gorman JM. Mechanisms underlying memory impairment in schizophrenia. Psychol Med 1997;27:383-93.
93. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997;42:664-8.
94. D'Souza DC, Gil R, Belger A, Zimmerman L, Tracy L, Larvey K, et al. Glycine-ketamine interactions in healthy humans. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Kona, Hawaii, December 1997.
95. Anand A, Charney DS, Cappiello A, Berman RM, Oren DA, Krystal JH. Lamotrigine reduces the psychotomimetic - but not the mood elevating - effects of ketamine in humans. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Kona, Hawaii, December 1997.
96. Krystal J, Karper L, D'Souza DC, Webb E, Bennett A, Abi- Dargham A, et al. Differentiating NMDA dysregulation in schizophrenia and alcoholism using ketamine. Presented at the 5th International Congress on Schizophrenia Research, Warm Springs, Virginia, April 1995.
97. Freund G, Anderson KJ. Glutamate receptors in the frontal cortex of alcoholics. Alcohol Clin Exp Res 1996;20:1165-72.
98. Krystal JH, Webb E, Petrakis I, Cooney N, Namanworth S, Trevisan L, et al. Blunted NMDA antagonist responses in recently detoxified alcoholics. Presented at the 1995 meeting of the Research Society on Alcoholism, Steamboat Springs, Colorado, June 1995.
99. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30.
100. Chandy KG, Fantino E, Wittekindt O, Kalman K, Tong LL, Ho TH, et al. Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder? Mol Psychiatry 1998; 3:32-7.
101. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia- thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990;85:119-46.
102. Krystal JH, Abi-Dargham A, Lamelle M, Moghaddam B. Pharmacologic model psychoses. In: Charney DS, Nestler E, Bunney BS, eds. Neurobiology of mental illness. New York: Oxford University Press, 1992:214-224.
103. Kornhuber J, Weller M. Psychotogenicity and N-methyl-D- aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997;41:135-44.
104. Greenamyre JT, O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991;48:977-81.
105. Olney JW, Price MT, Labruyere J, Salles KS, Frierdich G, Mueller M, et al. Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists. Eur J Pharmacol 1987;142:319-20.
106. Anonymous. Parkinson's disease and amantadine hydrochloride. JAMA 1969;208:1180-1.
107. Parkes JD, Calver DM, Zilkha KJ, Knill-Jones RP. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1970;1:259-62.
108. Verhagen Metman L, Del Dotto P, Natte R, Van den Munckhof P, Chase TN. Dextromethorphan improves levodopa- induced dyskinesias in Parkinson's disease. Neurology 1998; 51:203-6.
109. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-61.
110. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neur Transm Park Dis Dement Sect 1992; 4:277-82.
111. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46:1551-6.
112. Brooks S, Kaur S, Starr BS, Starr MS. Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease? J Neur Transm Gen Sect 1996;103:737-48.
113. Weihmuller FB, Ulas J, Nguyen L, Cotman CW, Marshall JF. Elevated NMDA receptors in parkinsonian striatum. Neuroreport 1992;3:977-80.
114. Ulas J, Weihmuller FB, Brunner LC, Joyce JN, Marshall JF, Cotman CW. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J Neurosci 1994; 14:6317-24.
115. Menegoz M, Lau LF, Herve D, Huganir RL, Girault JA. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 1995;7:125-8.
116. Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson's disease. Mol Neurobiol 1996;12:73-94.
117. Hershey T, Black KJ, Stambuk MK, Carl JL, McGee-Minnich LA, Perlmutter JS. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc Natl Acad Sci USA 1998;95:12016-21.
118. Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995;346:1383-7.
119. Benabid AL, Pollak P, Gervason C, Hoffmann D, Gao DM, Hommel M, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991;337:403-6.
120. Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm Suppl 1995;46:97-105.
121. 2A receptor blockade. J Pharmacol Exp Ther 1996;277:1541-9.
122. Moghaddam B, Bolinao ML. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse 1994;18: 337-42.
123. Gusella JF, MacDonald ME. Huntingtin: a single bait hooks many species. Curr Opin Neurobiol 1998;8:425-30.
124. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306:234-8.
125. Calabresi P, Centonze D, Pisani A, Sancesario G, Gubellini P, Marfia GA, et al. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol 1998;43:586-97.
126. Kosinski CM, Cha JH, Young AB, Persichetti F, MacDonald M, Gusella JF, et al. Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. Exp Neurol 1997;144:239-47.
127. Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996; 6:751-8.
128. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988;85: 5733-7.
129. Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clin Neuropharmacol 1992;15: 148-51.
130. Dure LS IV, Young AB, Penney JB. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann Neurol 1991;30:785-93.
131. Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996;11:273-7.
132. Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJ, Hariharan M, et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 1997;49:153-61.
133. Lovinger DM, White G, Weight FF. Ethanol inhibits NMDA- activated ion current in hippocampal neurons. Science 1989; 243:1721-4.
134. Grant KA, Lovinger DM. Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. Clin Neurosci 1995;3:155-64.
135. Holter SM, Danysz W, Spanagel R. Evidence for alcohol anti- craving properties of memantine. Eur J Pharmacol 1996; 314:R1-2.
136. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995;152:332-40.
137. Krystal JH, Petrakis IL, D'Souza DC, Trevisan L, Krasnicki S, Charney DS. Interactive effects of high dose intravenous glycine and oral D-cycloserine in healthy human subjects. Presented at the 1997 annual meeting of the Society of Biological Psychiatry, San Diego, May 1997.
138. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by Acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53: 673-80.
139. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, et al. Comparison of Acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-42.
140. Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav 1989;32:607-11.
141. Rosen MI, McMahon TJ, Woods SW, Pearsall HR, Kosten TR. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur J Pharmacol 1996;307:251-7.
142. Rasmussen K, Kendrick WT, Kogan JH, Aghajanian GK. A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology 1996;15:497-505.
143. Rasmussen K. The role of the locus coeruleus and N-methyl- D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Neuropsychopharmacology 1995;13:295-300.
144. Rasmussen K, Fuller RW, Stockton ME, Perry KW, Swinford RM, Ornstein PL. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur J Pharmacol 1991;197:9-16.
145. Rasmussen K, Krystal JH, Aghajanian GK. Excitatory amino acids and morphine withdrawal: differential effects of central and peripheral kynurenic acid administration. Psychopharmacology 1991;105:508-12.
146. Aghajanian GK, Kogan JH, Moghaddam B. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study. Brain Res 1994; 636:126-30.
147. Rasmussen K, Aghajanian GK. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Res 1989;505:346-50.
148. Vandergriff J, Rasmussen K. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 1999;38:217-22.
149. Ushijima I, Kobayashi T, Suetsugi M, Watanabe K, Yamada M, Yamaguchi K. Cocaine: evidence for NMDA-, β-carboline- and dopaminergic-mediated seizures in mice. Brain Res 1998;797:347-50.
150. Post RM, Kopanda RT. Cocaine, kindling, and psychosis. Am J Psychiatry 1976;133:627-34.
151. 1 receptors modulate glutamate transmission in the ventral tegmental area. J Neurosci 1995;15: 5379-88.
152. 1 dopamine receptor agonists produce biphasic effects on glutamate efflux in rat ventral tegmental area: modification by repeated amphetamine administration. J Neurochem 1998;70:198-209.
153. Fitzgerald LW, Ortiz J, Hamedani AG, Nestler EJ. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J Neurosci 1996;16:274-82.
154. Roche KW, Tingley WG, Huganir RL. Glutamate receptor phosphorylation and synaptic plasticity. Curr Opin Neurobiol 1994;4:383-8.
155. Kalivas PW. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Depend 1995;37:95-100.
156. Karler R, Calder LD, Chaudhry IA, Turkanis SA. Blockade of "reverse tolerance" to cocaine and amphetamine by MK- 801. Life Sci 1989;45:599-606.
157. Post RM, Weiss SR, Smith M, Rosen J, Frye M. Stress, conditioning, and the temporal aspects of affective disorders. Ann NYAcad Sci 1995;771:677-96.
158. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993;60:1650-7.
159. Takahata R, Moghaddam B. Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. J Neurochem 1998;71:1443-9.
160. Krystal JH, Moghaddam B, Breier A, Goldman-Rakic P, McElvey J. Glutamate, dopamine, the frontal cortex, and schizophrenia. Presented at the 53rd annual meeting of the Society of Biological Psychiatry, Toronto, May 1998.
161. Alterman AI, Droba M, Antelo RE, Cornish JW, Sweeney KK, Parikh GA, et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992;31:19-29.
162. Tennant FS Jr, Sagherian AA. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch Int Med 1987;147:109-12.
163. Kosten TR, Morgan CM, Falcione J, Schottenfeld RS. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992;49:894-8.
164. Kampman K, Volpicelli JR, Alterman A, Cornish J, Weinrieb R, Epperson L, et al. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend 1996;41:25-33.
165. Robbins SJ, Ehrman RN, Childress AR, O'Brien CP. Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. Addict Behav 1992;17:491-9.
166. White G, Lovinger DM, Peoples RW, Weight FF. Inhibition of N-methyl-D-aspartate activated ion current by desmethylimipramine. Brain Res 1990;537:337-9.
167. Weddington WW Jr, Brown BS, Haertzen CA, Hess JM, Mahaffey JR, Kolar AF, et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991;17: 137-52.
168. Kosten TR, Morgan CH, Schottenfeld RS. Amantadine and desipramine in the treatment of cocaine abusing methadone maintained patients. NIDA Res Monogr 1991;105:510-1.
169. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996;29: 23-6.
170. Watanabe Y, Weiland NG, McEwen BS. Effects of adrenal steroid manipulations and repeated restraint stress on dynorphin mRNA levels and excitatory amino acid receptor binding in hippocampus. Brain Res 1995;680:217-25.
171. Nowak G, Redmond A, McNamara M, Paul IA. Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex. J Neurochem 1995;64:925-7.
172. Yoneda Y, Han D, Ogita K. Preferential induction by stress of the N-methyl-D-aspartate recognition domain in discrete structures of rat brain. J Neurochem 1994;63:1863-71.
173. Krugers HJ, Koolhaas JM, Bohus B, Korf J. A single social stress-experience alters glutamate receptor-binding in rat hippocampal CA3 area. Neurosci Lett 1993;154:73-7.
174. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1-10.
175. Trullas R, Jackson B, Skolnick P. Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine- insensitive glycine receptors. Pharmacol Biochem Behav 1989;34:313-6.
176. Papp M, Moryl E. New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol 1993;45:549-53.
177. Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994;263:1-7.
178. Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993;265: 1380-6.
179. Paul IA, Trullas R, Skolnick P, Nowak G. Down-regulation of cortical β-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology 1992;106: 2857.
180. Paul IA, Layer RT, Skolnick P, Nowak G. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur J Pharmacol 1993;247: 305-11.
181. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994;269:95-102.
182. Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl- D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995;675:157-64.
183. Cappello A, Charney DS, Berman R, AnandA, Miller H, Heninger GR, et al. NMDA receptor function in major depression. Presented at the 52nd annual meeting of the Society of Biological Psychiatry, San Diego, May 1997.
184. Crane GE. Cycloserine as an antidepressant agent. Am J Psychiatry 1959;115:1025-6.
185. Vale S, Espejel MA, Dominguez JC. Amantadine in depression [Letter]. Lancet 1971;2:437.
186. Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear- potentiated startle by NMDA antagonists in the amygdala. Nature 1990;345:716-8.
187. Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res 1994;655:251-4.
188. Sapolsky RM. Glucocorticoids, hippocampal damage and the glutamatergic synapse. Prog Brain Res 1990;86:13-23.
189. Armanini MP, Hutchins C, Stein BA, Sapolsky RM. Glucocorticoid endangerment of hippocampal neurons is NMDA- receptor dependent. Brain Res 1990;532:7-12.
190. Elliott EM, Mattson MP, Vanderklish P, Lynch G, Chang I, Sapolsky RM. Corticosterone exacerbates kainate-induced alterations in hippocampal tau immunere activity and spectrin proteolysis in vivo. J Neurochem 1993;61:57-67.
191. Elliott EM, Sapolsky RM. Corticosterone enhances kainic acid-induced calcium elevation in cultured hippocampal neurons. J Neurochem 1992;59:1033-40.
192. Bremner JD, Randall P, Vermetten E, Staib L, Bronen RA, Mazure C, et al. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse - a preliminary report. Biol Psychiatry 1997;41:23-32.
193. Bremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 1995;152:973-81.
194. Krystal JH, Bennett AL, Bremner JD, Southwick SM, Charney DS. Toward a cognitive neuroscience of dissociation and altered memory functions in post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and clinical consequences of stress: from normal adaptation to posttraumatic stress disorder. Philadelphia: Lippincott-Raven, 1995:239-69.
195. Chambers AC, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and PTSD: toward a neurobiology of dissociation. Semin Clin Neuropsychiatry [In press].
196. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281:1349-52.
197. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13:9-19.
198. Malhotra AK, Finals DA, Adler CM, Elman I, Clifton A, Pickar D, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997;17:141-50.
199. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
200. Konig P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996;33:80-4.
201. Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients: a double-blind cross-over study. Br J Psychiatry 1995;166:241-3.
202. DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976;33:599-602.
203. Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: un- competitive antagonism. J Physiol 1997;499:27-46.
204. Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M. Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport 1993;4:687-90.
205. Geter-Douglass B, Witkin JM. Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice. Psychopharmacology 1997;133:43-50.
206. Herrling P, ed. Excitatory amino acids: clinical results with antagonists. San Diego: Academic, 1997.
207. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978;135:1081-4.
208. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995;6:869-72.
209. Warfel D, Lahti AC, Michaelidis T, Renwick H, Bean J, Weiler MA, et al. Follow-up patients who receive challenge with ketamine as a part of a research study. Presented at the 7th International Congress on Schizophrenia Research, Santa Fe, New Mexico, April 1999.
210. Adler CM, Malhotra AK, Elman I, Carson R, Pickar D, Breier A. Effects of the N-methyl-D-aspartate receptor antagonist ketamine on striatal dopamine release in schizophrenia. Presented at the 7th International Congress on Schizophrenia Research, Santa Fe, New Mexico, April 1999.
211. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996;169:610-7.
212. Sklar GS, Zukin SR, Reilly TA. Adverse reactions to ketamine anaesthesia: abolition by a psychological technique. Anaesthesia 1981;36:183-7.
213. Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic- Todorovic V, Olney JW. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Presented at the 28th annual meeting of the Society for Neuroscience, Los Angeles, November 1998.
214. Krystal J, Petrakis I, Krasnicki S, Trevisan L, Boutros N, D'Souza DC. Altered responses to agonists of the strychnine- insensitive glycine NMDA coagonist (SIGLY) site in recently detoxified alcoholics [Abstract]. Alcohol Clin Exp Res 1998; 22(3, suppl):94A.